Rasagiline for motor complications in Parkinson's disease.
Clarke
Carl E
CE
University of Birmingham and Department of Neurology, City Hospital, Birmingham B18 7QH, UK. c.e.clarke@bham.ac.uk
D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000008:administration & dosage*; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage*; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D004791:Enzyme Inhibitors; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D009570:Nitriles; C031967:rasagiline; D007980:Levodopa; C071192:entacapone